Guangbao Li1, Jianwen Yin1, Zutong Wu1, Shizhong Li1, Aijun He1, Zhenzhen Sun2. 1. Department of Orthopedics, The First Affiliated Hospital of Shaoyang University Shaoyang 422000, P. R. China. 2. Department of Peadiatrics, The First Affiliated Hospital of Shaoyang University Shaoyang 422000, P. R. China.
Abstract
OBJECTIVE: To investigate the expression level of serum miRNA-192-5p and its clinical value in the diagnosis and care of patients with multiple myeloma (MM). METHODS: Eighty-eight patients with MM admitted to our hospital from June 2017 to April 2020 were selected as the observation group. In addition, 70 patients who received osteoporosis testing in our hospital in the corresponding period but were excluded from having MM and haematological malignancy were selected as the control group. The relative expression level of serum miRNA-192-5p was detected. The expression level of serum miRNA and its correlation with patient-related clinical parameters were compared and analyzed. The ROC curve was used to analyze its diagnostic efficacy for MM. RESULTS: The relative expression level of serum miRNA-192-5p in MM patients was remarkably lower than that in the control group (P < 0.05); the AUC area of serum miRNA-192-5p in patients with a diagnosis of MM was 0.853, with a cutoff value of 0.72, the sensitivity of 86.30%, and the specificity of 81.20%, P = 0.030. The relative expression level of miRNA-192-5p in the serum of patients with high β2-MG and creatinine levels was markedly reduced compared to that in patients with low β2-MG levels (P < 0.05); the relative expression level of miRNA-192-5p in the serum of patients with low hemoglobin and albumin levels was markedly reduced compared to that in patients with normal hemoglobin and albumin (P < 0.05); and there was significantly negative correlation between the relative expression level of miRNA-192-5p in the serum of MM patients and IgG and IgA levels, respectively (P < 0.05). CONCLUSION: miRNA-192-5p may serve as an auxiliary diagnostic tool in the diagnosis of MM. Furthermore, because there is certain correlation between serum miRNA-192-5p and MM progression and prognosis, it may be regarded as a novel marker for MM monitoring. AJTR
OBJECTIVE: To investigate the expression level of serum miRNA-192-5p and its clinical value in the diagnosis and care of patients with multiple myeloma (MM). METHODS: Eighty-eight patients with MM admitted to our hospital from June 2017 to April 2020 were selected as the observation group. In addition, 70 patients who received osteoporosis testing in our hospital in the corresponding period but were excluded from having MM and haematological malignancy were selected as the control group. The relative expression level of serum miRNA-192-5p was detected. The expression level of serum miRNA and its correlation with patient-related clinical parameters were compared and analyzed. The ROC curve was used to analyze its diagnostic efficacy for MM. RESULTS: The relative expression level of serum miRNA-192-5p in MMpatients was remarkably lower than that in the control group (P < 0.05); the AUC area of serum miRNA-192-5p in patients with a diagnosis of MM was 0.853, with a cutoff value of 0.72, the sensitivity of 86.30%, and the specificity of 81.20%, P = 0.030. The relative expression level of miRNA-192-5p in the serum of patients with high β2-MG and creatinine levels was markedly reduced compared to that in patients with low β2-MG levels (P < 0.05); the relative expression level of miRNA-192-5p in the serum of patients with low hemoglobin and albumin levels was markedly reduced compared to that in patients with normal hemoglobin and albumin (P < 0.05); and there was significantly negative correlation between the relative expression level of miRNA-192-5p in the serum of MMpatients and IgG and IgA levels, respectively (P < 0.05). CONCLUSION:miRNA-192-5p may serve as an auxiliary diagnostic tool in the diagnosis of MM. Furthermore, because there is certain correlation between serum miRNA-192-5p and MM progression and prognosis, it may be regarded as a novel marker for MM monitoring. AJTR
Authors: Teresa Ezponda; Daphné Dupéré-Richer; Christine M Will; Eliza C Small; Nobish Varghese; Tej Patel; Behnam Nabet; Relja Popovic; Jon Oyer; Marinka Bulic; Yupeng Zheng; Xiaoxiao Huang; Mrinal Y Shah; Sayantan Maji; Alberto Riva; Manuela Occhionorelli; Giovanni Tonon; Neil Kelleher; Jonathan Keats; Jonathan D Licht Journal: Cell Rep Date: 2017-10-17 Impact factor: 9.423
Authors: J Xu; N Pfarr; V Endris; E K Mai; N H Md Hanafiah; N Lehners; R Penzel; W Weichert; A D Ho; P Schirmacher; H Goldschmidt; M Andrulis; M S Raab Journal: Oncogenesis Date: 2017-05-15 Impact factor: 7.485